07:00 , Jul 21, 2014 |  BioCentury  |  Politics, Policy & Law

Debating drug pricing

Payers and politicians are waving the cost of Gilead Sciences Inc. 's Sovaldi sofosbuvir like a bloody shirt, claiming it is inflicting intolerable injury to the healthcare system. They are also using it to rally...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

What might fit

What might fit Company Product Description Indication Status Arca biopharma Inc. (NASDAQ:ABIO) Gencaro bucindolol Non-selective beta blocker Chronic heart failure FDA complete response letter in June requests additional clinical trials AtheroGenics Inc. (A) AGI-1067 Small...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

Questions of the heart

On its way to becoming a bellwether biotech, Gilead Sciences Inc. saw its market cap jump some 50% in less than two years, climbing from about $26 billion in early 2006 to about $40 billion...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Company News

AtheroGenics endocrine, cardiovascular news

AtheroGenics said it does not expect to have any remaining funds to distribute to shareholders after the sale of the company's assets. AtheroGenics and its financial advisor, Merriman Curhan Ford & Co. has received initial...
07:00 , Oct 13, 2008 |  BC Week In Review  |  Company News

AtheroGenics endocrine, cardiovascular news

AtheroGenics filed for Chapter 11 bankruptcy and hired Merriman Curhan Ford to assist with the sale of the company or its assets. The biotech said the filing was necessary due to its "substantial debt burden."...
07:00 , Oct 13, 2008 |  BioCentury  |  Finance

Ebb & Flow

Companies about to be acquired generally trade just under the acquisition price. But in the case of ImClone (NASDAQ:IMCL), concerns about the credit market - or maybe just general market anxiety - appear to be...
01:05 , Oct 8, 2008 |  BC Extra  |  Company News

AtheroGenics files for bankruptcy

AtheroGenics (NASDAQ:AGIX) filed for Chapter 11 bankruptcy and hired Merriman Curhan Ford to assist with the sale of the company or its assets. AtheroGenics' lead compound is AGI-1067, a small molecule that blocks vascular cell...
07:00 , Aug 4, 2008 |  BC Week In Review  |  Clinical News

AGI-1067: Phase III data

Top line data from the double-blind, international Phase III ANDES trial in 887 patients who completed 6 months of treatment showed that 75 and 150 mg daily doses of oral AGI-1067 met the primary endpoint...
07:00 , Aug 4, 2008 |  BioCentury  |  Finance

Ebb & Flow

Lilly’s project finance Eli Lilly (NYSE:LLY) pulled a play from the biotech book when it did a deal with hedge fund TPG-Axon and Quintiles’ NovaQuest unit for $300 million in funding to conduct trials of...
01:46 , Aug 1, 2008 |  BC Extra  |  Clinical News

AtheroGenics gains on AGI-1067 data

AtheroGenics (NASDAQ:AGIX) gained $0.29 (53%) to $0.84 on Thursday after AGI-1067 met the primary endpoint of significantly reducing HbA1c levels in the Phase III ANDES trial to treat Type II diabetes. Top line data from...